20/20 GeneSystems Inc.
TWTG
Other OTC3.50
USD
- -
- -
20/20 GeneSystems Inc.
TWTG
(Other OTC)
Recent
price
3.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- 20/20 GeneSystems Inc, headquartered in Rockville, Maryland, is a digital diagnostics company specializing in the development and commercialization of advanced laboratory-based diagnostic tests powered by machine learning and real-world data. Its core product portfolio includes OneTest, a blood test designed to aid in the early detection of multiple cancers through tumor marker analysis, as well as COVID-19 testing solutions comprising PCR viral tests and rapid point-of-care antibody and antigen tests. The company focuses on early-stage disease detection and prevention, leveraging AI algorithms to enhance the accuracy and efficiency of clinical lab testing. Founded in 2000, 20/20 GeneSystems also works on novel diagnostics for biological threat detection and chronic disease biomarkers. Recent major changes include the company’s strategic engagement with ClearingBid, a platform that democratizes investment in IPOs by enabling individuals and institutions to invest on equal terms. Additionally, the company has been actively raising funds through various rounds, most notably raising up to $5 million in 2024 through a private placement, enhancing its capital to expand product development and commercial activities. In early 2025, 20/20 GeneSystems underwent a rebranding to 20/20 BioLabs as it continues expanding its portfolio of AI-powered blood tests targeting cancer, chronic disease, and inflammation biomarkers. A planned merger with Longevity Health Holdings was reported but subsequently did not materialize, reflecting a focus on internal growth and innovative diagnostics launches. The company maintains collaborations with research institutions and is advancing tests aimed at screening smokers for lung cancer and developing guidance for improved health outcomes based on biomarker profiles. Operating primarily in the biotechnology and clinical diagnostics industry, 20/20 serves a global market with products aimed at healthcare providers, researchers, and life sciences organizations. Its technology platform integrates multiplex biomarker analysis with AI-driven machine learning models to provide personalized medicine solutions, early cancer detection, and pandemic response testing capabilities. The company’s strategic initiatives reflect continuous innovation in digital diagnostics and strengthening market positioning in early disease detection with a commitment to expanding clinical utility through machine learning advancements.